Dept. of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Gut Microbes. 2023 Jan-Dec;15(1):2221452. doi: 10.1080/19490976.2023.2221452.
Regardless of the global progress in early diagnosis and novel therapeutic regimens, breast carcinoma poses a devastating threat, and the advances are somewhat marred by high mortality rates. Breast cancer risk prediction models based on the known risk factors are extremely useful, but a large number of breast cancers develop in women with no/low known risk. The gut microbiome exerts a profound impact on the host health and physiology and has emerged as a pivotal frontier in breast cancer pathogenesis. Progress in metagenomic analysis has enabled the identification of specific changes in the host microbial signature. In this review, we discuss the microbial and metabolomic changes associated with breast cancer initiation and metastatic progression. We summarize the bidirectional impact of various breast cancer-related therapies on gut microbiota and vice-versa. Finally, we discuss the strategies to modulate the gut microbiota toward a more favorable state that confers anticancer effects.
尽管在早期诊断和新的治疗方案方面取得了全球进展，但乳腺癌仍然构成了毁灭性的威胁，而这些进展在一定程度上因高死亡率而受到影响。基于已知风险因素的乳腺癌风险预测模型非常有用，但大量乳腺癌发生在无/低已知风险的女性中。肠道微生物组对宿主健康和生理机能产生深远影响，已成为乳腺癌发病机制的关键前沿领域。宏基因组分析的进展使得能够识别宿主微生物特征的特定变化。在这篇综述中，我们讨论了与乳腺癌发生和转移进展相关的微生物和代谢组学变化。我们总结了各种乳腺癌相关治疗对肠道微生物组的双向影响以及反之亦然。最后，我们讨论了调节肠道微生物组向更有利于发挥抗癌作用的状态的策略。
Zotero 插件
